Williams Cancer Institute

SYNC-T Technology: Advancements in Cancer Therapy

Syncromune® Inc., a leading biopharmaceutical company, has unveiled promising outcomes from its Phase 1 trial of SYNC-T™ therapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. SYNC-T, a cutting-edge personalized treatment tailored for solid tumor cancers, demonstrated an impressive overall response rate (ORR) of 85% in patients with metastatic castrate-resistant prostate cancer […]